Xenon at TD Cowen summit: epilepsy gains, psychiatry pause

Xenon Pharmaceuticals (XENE) submitted a New Drug Application for azetukalner in treating focal seizures, while pausing new enrollments in depression studies due to adverse events. The epilepsy program is supported by positive Phase 2b and 3 trial results, with seizure frequency reductions of 53.2% and 34.5% for 25 mg and 15 mg doses, respectively. The psychiatric program's future depends on addressing tolerability issues and upcoming trial results in 2027.

Xenon Pharmaceuticals (XENE) shares dropped 30% after pausing Phase 3 depression trials for azetukalner due to safety concerns, prompting a downgrade from Deutsche Bank analyst David Hoang.

Xenon Pharmaceuticals (XENE) submitted a New Drug Application for azetukalner to treat focal seizures, supported by positive clinical trial data. Simultaneously, the company paused new patient enrollment in depression studies due to neuropsychiatric adverse events. Analysts believe the stock's 29.22% drop is overblown, citing comparable safety profiles in approved drugs.

Xenon Pharmaceuticals (XENE) halted enrollment in a depression study due to adverse events, causing its stock to drop 29% to $40.60. The company submitted a new drug application for its epilepsy treatment, azetukalner, which showed promising results in reducing seizures. Analysts cut price targets but remain optimistic about the epilepsy drug's potential.

U.S. stocks fell midday, with the Dow down 0.45% and NASDAQ down 0.16%. Xenon Pharmaceuticals (XENE) shares dropped 29% after pausing psychiatry studies. Other movers include SECZ (+10%), PURR (+6%), and MG (+6%). U.S. industrial production was unchanged in August, missing estimates.

Xenon Pharmaceuticals (XENE) halted clinical trials for azetukalner, a potential epilepsy treatment, due to unexpected side effects. The stock, which had surged 50% in March on positive data, fell to a six-month low. The company cited safety concerns as the reason for the pause.